ARTICLE | Company News
Esprit, Novavax deal
May 22, 2006 7:00 AM UTC
NVAX granted Esprit exclusive rights to market Androsorb in North America to treat female hypoactive sexual desire disorder (HSDD). The micellar nanoparticle testosterone lotion is in Phase II testing...